DRKS00020514
Completed
Not Applicable
Rituximab in pediatric rheumatic diseases: 2 years follow up for immunological long-term effects using a standardized screening and safety protocol.
(Non-profit) Verein: Hilfe für das rheumakranke Kind e.V.0 sites21 target enrollmentStarted: January 17, 2020Last updated:
Overview
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- (Non-profit) Verein: Hilfe für das rheumakranke Kind e.V.
- Enrollment
- 21
Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Observational
Eligibility Criteria
- Ages
- one to 18 Years (—)
- Sex
- All
Inclusion Criteria
- •Severe and/or refractory pediatric rheumatic diseases based on antobody\-mediated pathogenesis.
Exclusion Criteria
- •Acute and severe infection. Primary immunodeficiency.
Investigators
Similar Trials
Completed
Not Applicable
The efficacy of rituximab for children with refractory nephrotic syndromesteroid dependent nephrotic synrdome and frequent relapsing nephrotic syndromeJPRN-UMIN000009411Department of Pediatrics, Kobe University Graduate School of Medicine20
Active, not recruiting
Phase 1
Rituximab in the Treatment of Refractory Adult and Juvenile Dermatomyositis (DM)and Adult Polmyositis (PM) - Rituximab in myositis (RIM)Adult polymyositis or adult dermatomyositis or juvenile dermatomyositis.MedDRA version: 9.1Level: LLTClassification code 10036102Term: PolymyositisEUCTR2006-000078-65-CZKarolinska University Hospital202
Active, not recruiting
Phase 1
Rituximab in the Treatment of Refractory Adult and Juvenile Dermatomyositis (DM) and Adult Polymyositis (PM) - Rituximab in myositisAdult polymyositis or adult dermatomyositis or juvenile dermatomyositisMedDRA version: 8.1Level: LLTClassification code 10036102Term: PolymyositisEUCTR2006-000078-65-GBKarolinska University Hospital202
Active, not recruiting
Not Applicable
Rituximab in the Treatment of Refractory Adult and Juvenile Dermatomyositis (DM) and Adult Polymyositis (PM) - Rituximab in myositisAdult polymyositis or adult dermatomyositis or juvenile dermatomyositisMedDRA version: 8.1Level: LLTClassification code 10036102Term: PolymyositisEUCTR2006-000078-65-SEKarolinska University Hospital202
Active, not recruiting
Not Applicable
Re-Treatment with Rituximab in patients with rheumatoid arthritis who have had an inadequate response to not more than one aTNF (extension study to ML19070) - Efficacy of re-therapy in anti-TNFalpha IRRheumatoid arthritisMedDRA version: 9.1Level: PTClassification code 10039073Term: Rheumatoid arthritisEUCTR2006-006746-33-DERoche Pharma AG240